Effect of changing therapy from agalsidase beta to agalsidase alfa in patients with Fabry disease

被引：0
|
作者：
West, M [1 ]
Lemoine, K [1 ]
机构：
[1] Dalhousie Univ, Dept Med, Halifax, NS, Canada
来源：
ACTA PAEDIATRICA | 2006年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [21] Agalsidase alfa for enzyme-replacement therapy in Fabry disease
    Mehta, Atul
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (05) : 641 - 652
  • [22] Evaluation of glycosphingolipid clearance in patients with Fabry disease treated with agalsidase alfa who switched to agalsidase beta (the INFORM study)
    Barranger, John A.
    Gambello, Michael J.
    Goker-Alpan, Ozlem
    Maegawa, Gustavo H. B.
    Nedd, Khan J.
    Gruskin, Daniel J.
    Blankstein, Larry
    Weinreb, Neal J.
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S24 - S24
  • [23] Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
    Ramaswami, U.
    Wendt, S.
    Pintos-Morell, G.
    Parini, R.
    Whybra, C.
    Leon Leal, J. A.
    Santus, F.
    Beck, M.
    ACTA PAEDIATRICA, 2007, 96 (01) : 122 - 127
  • [24] Is there a neutralizing effect of antibodies against agalsidase alfa and agalsidase beta?
    Mengel, E.
    Baron, K.
    Kalkum, G.
    Kampmann, C.
    Beck, M.
    ACTA PAEDIATRICA, 2007, 96 : 108 - 108
  • [25] Home infusion therapy with agalsidase alfa for patients with Fabry disease in Germany and Austria
    Lachmann, Anja
    Kurschat, Christine
    Fritsch, Almut
    Lagler, Florian
    Sunder-Plassmann, Gere
    Martus, Peter
    Kralewski, Martina
    Hennermann, Julia B.
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S94 - S94
  • [26] Agalsidase Alfa and Kidney Dysfunction in Fabry Disease
    West, Michael
    Nicholls, Kathy
    Mehta, Atul
    Clarke, Joe T. R.
    Steiner, Robert
    Beck, Michael
    Barshop, Bruce A.
    Rhead, William
    Mensah, Robert
    Ries, Markus
    Schiffmann, Raphael
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05): : 1132 - 1139
  • [27] Clinical outcomes after switching to migalastat from agalsidase alfa or agalsidase beta in patients with Fabry disease: Post hoc analysis from ATTRACT
    Sunder-Plassmann, Gere
    Jovanovic, Ana
    Feldt-Rasmussen, Ulla
    Jain, Vipul
    Peceny, Markus
    Skuban, Nina
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S141 - S141
  • [28] Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha
    Reidt, S.
    Namdar, M.
    Serra, A.
    Krayenbuehl, P. A.
    Gruner, C.
    Keller, D. I.
    Luescher, T. F.
    Schmied, C.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (02) : 205 - 207
  • [29] Hearing loss in Fabry disease: The effect of Agalsidase alfa replacement therapy.
    Richfield, L
    Hajioff, D
    Enever, Y
    Quiney, R
    Mehta, AB
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 579 - 579
  • [30] Agalsidase alfa: specific treatment for Fabry disease
    Mehta, A
    HOSPITAL MEDICINE, 2002, 63 (06): : 347 - 350
12345